This came to an end with the discovery and FDA approval of the irreversible covalent KRAS G12C inhibitor, Sotorasib (AMG 510), for the treatment of NSCLC, in 2021 [15]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.